EcoDrugPlus

Egl Nine Homolog 1-Like

Ensembl ID : ENSDCDG00000034911
Gene Symbol: LOC114769697
2 Cross references
191 Possible Orthologues:

Egl Nine Homolog 1-Like

Ensembl ID : ENSDCDG00000013919
Gene Symbol: LOC114786091
3 Cross references
219 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSDCDG00000002127
Gene Symbol: EGLN3
3 Cross references
203 Possible Orthologues:

Endothelial Pas Domain Protein 1

Ensembl ID : ENSDCDG00000020764
Gene Symbol: EPAS1
3 Cross references
213 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSDCDG00000030615
Gene Symbol: ECE1
3 Cross references
231 Possible Orthologues:

Endothelin Receptor Type A

Ensembl ID : ENSDCDG00000026126
Gene Symbol: EDNRA
3 Cross references
205 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSDCDG00000022897
Gene Symbol: EDNRB
3 Cross references
199 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSDCDG00000022616
Gene Symbol: EDNRB
1 Cross references
199 Possible Orthologues:

Endothelin Receptor Type B-Like

Ensembl ID : ENSDCDG00000020551
Gene Symbol: LOC114782600
3 Cross references
201 Possible Orthologues:

Endothelin Receptor Type B-Like

Ensembl ID : ENSDCDG00000031310
Gene Symbol: LOC114791067
3 Cross references
156 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSDCDG00000035776
Gene Symbol: EZH2
3 Cross references
240 Possible Orthologues:

Epidermal Growth Factor Receptor-Like

Ensembl ID : ENSDCDG00000035745
Gene Symbol: LOC114769440
2 Cross references
213 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).